Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex

Neuron

Volumn 28, Issue 1, 2000, Pages 53-67

  Mirnics, Károly ^a   Middleton, Frank A ^a   Marquez, Adriana ^a   Lewis, David A ^a   Levitt, Pat ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N ETHYLMALEIMIDE; SYNAPSIN II;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; NERVE ENDING; NEUROTRANSMISSION; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0033637841     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(00)00085-4     Document Type: Article

References (97)

1. GABAA receptor subunit gene expression in human prefrontal cortex: Comparison of schizophrenics and controls
2. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
3. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia
4. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
5. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects
6. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
7. Synchronous development of pyramidal neuron dendritic spines and parvalbumin-immunoreactive chandelier neuron axon terminals in layer III of monkey prefrontal cortex
8. Pieces of the schizophrenia puzzle fall into place
9. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neurolepticnaive patients
10. Synaptic vesicle docking and fusion
11. Pre- and postmortem influences on brain RNA
12. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of working memory cortical network in schizophrenia
13. Chromosome 17 and hereditary dementia: Linkage studies in three non-Alzheimer families and kindreds with late-onset FAD
14. Synaptogenesis in the neocortex of the newborn: The ultimate frontier for individuation?
15. Synaptogenesis in the prefrontal cortex of rhesus monkeys
16. Effects of repetitive transcranial magnetic stimulation over dorsolateral prefrontal and posterior parietal cortex on memory-guided saccades
17. Exploring the new world of the genome with DNA microarrays
18. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
19. Postnatal decrease in transforming growth factor alpha is associated with enlarged ventricles, deficient amygdaloid vasculature and performance deficits
20. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background
21. Schizophrenia
22. Inactivation of parietal and prefrontal cortex reveals interdependence of neural activity during memory-guided saccades
23. Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug treatment
24. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
25. The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains
26. Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia
27. Expression profiling using cDNA microarrays
28. Immuno-autoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia
29. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia
30. Cluster analysis and display of genome-wide expression patterns
31. Deficits in memory and motor performance in synaptotagmin IV mutant mice
32. Analysis of SCAMP1 function in secretory vesicle exocytosis by means of gene targeting in mice
33. Sex differences in inferior parietal lobule volume in schizophrenia
34. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia
35. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients
36. The small GTP-binding protein Rab3A regulates a late step in synaptic vesicle fusion
37. Normal cellular levels of synaptophysin mRNA expression in the prefrontal cortex of subjects with schizophrenia
38. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
39. Decreased dendritic spine density of prefrontal cortical pyramidal neurons in schizophrenia
40. Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging
41. The neuropathology of schizophrenia. A critical review of the data and their interpretation
42. Gene expression and neuronal activity in schizophrenia: A study of polyadenylated mRNA in the hippocampal formation and cerebral cortex
43. Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia
44. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
45. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia
46. Synaptic density in human frontal cortex - Developmental changes and effects of aging
47. Regional differences in synaptogenesis in human cerebral cortex
48. The genetics of mental illness: Implications for practice
49. The NIMH perspective: Next steps in schizophrenia research
50. Molecular genetics of human retinal dystrophies
51. Membrane fusion and exocytosis
52. Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I
53. Synergistic interactions between ampakines and antipsychotic drugs
54. A turning point in schizophrenia genetics
55. Reduced levels of synaptic proteins in the prefrontal cortex in schizophrenia
56. Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: A possible neurochemical basis for 'hypofrontality'
57. Is there a neuropathology of schizophrenia?
58. Catching up with schizophrenia: Natural history and neurobiology
59. SNARE proteins - Why so many, why so few?
60. What counts in brain aging? Design-based stereological analysis of cell number
61. Differential distribution of synapsin IIa and IIb mRNAs in vadous brain structures and the effect of chronic morphine administration on the regional expression of these isoforms
62. MRI anatomy of schizophrenia
63. Dopamine receptor transcript expression in striatum and prefrontal occipital cortex
64. Synapsin I gene expression in the adult rat brain with comparative analysis of mRNA and protein in the hippocampus
65. High rates or schizophrenia in adults with velo-cardio-facial syndrome
66. Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain
67. Total nerve cell number in neocortex in chronic schizophrenics and controls estimated using optical disectors
68. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia
69. 31P nuclear magnetic resonance spectroscopy: Neurodevelopment and schizophrenia
70. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects
71. Characterization of transcripts from the synapsin III gene locus
72. Search for schizophrenia succeptability genes
73. Neuronal and glial somal size in the prefrontal cortex: A postmortem morphometric study of schizophrenia and Huntington disease
74. Segregation analysis of schizophrenia and related disorders
75. Searching for genetic determinants in the new millennium
76. Essential functions of synapsins I and II in synaptic vesicle regulation
77. Volumetric measure of the frontal and temporal lobe regions in schizophrenia: Relationship to negative symptoms
78. Women and schizophrenia
79. The reduced neuropil hypothesis: A circuit based model of schizophrenia
80. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure
81. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17
82. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a three-dimensional, stereologic counting method
83. Inositol levels are decreased in postmortem brain of schizophrenic patients
84. Electrical stimulation of monkeys' prefrontal cortex during delayed-response performance
85. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients
86. The synaptic vesicle cycle: A cascade of protein-protein interactions
87. Age-related abnormalities in expression of mRNAs encoding synapsin 1A, synapsin 1B, and synaptophysin in the temporal cortex of schizophrenics
88. NSF function in neurotransmitter release involves rearrangement of the SNARE complex downstream of synaptic vesicle docking
89. Schizophrenia: Genes and environment
90. Retinitis pigmentosa: Defined from a molecular point of view
91. Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in schizophrenia
92. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence
93. From neuropathology to neurodevelopment
94. Schizophrenia: New phenes and new genes
95. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays
96. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia
97. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage